Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress

ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Third Quarter 2026 Financial Results and ZEVASKYN ® Commercial Progress – Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 – – 15 ZEVASKYN treatments completed since launch, including six during Q3 – - QTC network ex

Event · Earnings
Original reporting
Published Nov 9, 2026, 11:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 11:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ABEO
Bullish
high confidence
Mentioned
$ABEO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ABEOBullishMed
01

Why it matters

The earnings beat and financing improve liquidity, potentially supporting share price, while the acquisition expands pipeline.

02

Market read

First‑time earnings disclosure for a small‑cap biotech with material financing; relevant for traders tracking rare‑disease therapeutics.

03

What to watch

Future FDA milestones for ABO-801 and NTAP status could drive longer‑term upside.

Relevance 7/10Novelty 7/10Timing: post‑market November 9, 2026
AlphAI · Earnings readABEO · Q3 2026 · ended 2026-09-30

Abeona reports Q3 2026 ZEVASKYN net revenue of $13.5 million, up 18% sequentially, with net loss narrowing to $(4.8) million; cash fell to $134.9 million before a $30 million PIPE closed after quarter end

→Mixed quarter

Product revenue rose 18% sequentially to $13.5 million and the quarterly net loss narrowed sharply from $(20.2) million in Q2 2026. Against that, cash, cash equivalents and short-term investments declined from $146.8 million to $134.9 million, the company acquired ABO-801 with $20 million of common stock issued and $30 million payable on FDA approval, and the filing gives no gross margin or guidance figure.

Revenue
$13.5M
ZEVASKYN (product revenue, net)
$13.5M
18% increase q/q

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, net (Q3 2026)GAAP$13.5M18% increase–
Product revenue, net (Q3 2026, thousands)GAAP$13.49M––
Total revenues (Q3 2026)GAAP$13.49M––
Total revenues (nine months 2026)GAAP$33.59M––
Product revenue, net (nine months 2026)GAAP$33.59M––
License and other revenues (nine months 2025)GAAP— (nil)––
Cost of sales (Q3 2026)GAAP$5.7M––
Cost of sales (Q3 2026, thousands)GAAP$5.71M––
Cost of sales (nine months 2026)GAAP$12.59M––
Research and development (Q3 2026)GAAP$3.7M––
Research and development (Q3 2026, thousands)GAAP$3.67M––
Research and development (nine months 2026)GAAP$18.25M––
Selling, general and administrative (Q3 2026)GAAP$17.1M––
Selling, general and administrative (Q3 2026, thousands)GAAP$17.11M––
Selling, general and administrative (nine months 2026)GAAP$52.44M––
Total costs and expenses (Q3 2026)GAAP$26.49M––
Total costs and expenses (nine months 2026)GAAP$83.28M––
Loss from operations (Q3 2026)GAAP−$13.00M––
Loss from operations (nine months 2026)GAAP−$49.69M––
Interest income (Q3 2026)GAAP$2.26M––
Interest income (nine months 2026)GAAP$4.97M––
Interest expense (Q3 2026)GAAP−$557K––
Interest expense (nine months 2026)GAAP−$2.08M––
Change in fair value of warrant liabilities (Q3 2026)GAAP$6.51M––
Change in fair value of warrant liabilities (nine months 2026)GAAP$4.70M––
Gain from sale of priority review voucher, net (nine months 2025)GAAP— (nil)––
Income tax expense (benefit) (Q3 2026)GAAP$18K––
Income tax expense (benefit) (nine months 2026)GAAP$20K––
Net loss (Q3 2026)GAAP−$4.8M––
Net loss (Q3 2026, thousands)GAAP−$4.81M––
Net (loss) income (nine months 2026)GAAP−$42.07M––
Basic and diluted loss per common share (Q3 2026)GAAP$(0.08)––
Basic loss per common share (nine months 2026)GAAP$(0.74)––
Diluted loss per common share (nine months 2026)GAAP$(0.74)––
Cash, cash equivalents and short-term investments (September 30, 2026)GAAP$134.9M––
Total assets (September 30, 2026)GAAP$171.9M––
Total stockholders' equity (September 30, 2026)GAAP$125.9M––
ZEVASKYN patient treatments completed since launch (cumulative)other15––
ZEVASKYN patient treatments completed in Q3 2026other6––
ZEVASKYN QTC network sites (Q3 2026)othereight sites––

Segments

SegmentRevenueq/qy/y
ZEVASKYN (product revenue, net)The company states that broader qualified treatment center (QTC) participation supported increased ZEVASKYN treatment activity in the third quarter. Revenue was not recognized for one treatment because the associated batch did not meet the release criterion for the identity assay, as previously disclosed in August 2026.$13.5M18% increase–

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • Abeona issued to Ellodi Pharmaceuticals $20 million of Abeona common stock at closing of the APT-1011 (ABO-801) asset purchase, with no upfront cash consideration.
  • Abeona entered into a securities purchase agreement for a private placement of $30 million in gross proceeds before fees and expenses; the company states the net proceeds are for general corporate purposes, including pipeline development and ZEVASKYN commercialization.
  • The September 30, 2026 cash balance excludes the $30 million in gross proceeds from the private placement completed after quarter end.

What drove it

  • The company attributes increased ZEVASKYN treatment activity in Q3 2026 to broader QTC participation, with Children's Hospital of Philadelphia and the University of Texas Medical Branch completing first treatments and increasing QTCs with treatment experience from two to four.
  • The QTC network was expanded to eight sites, including Cincinnati Children's (activated July 2026) and University of Florida Health (activated September 2026).
  • New Technology Add-On Payment (NTAP) status for ZEVASKYN became effective October 1, 2026. The company states this designation is expected to help support patient access and hospital adoption among eligible Medicare beneficiaries, who represent approximately 10 percent of RDEB patients.
  • Research and development expense fell to $3.7 million in Q3 2026 from $5.0 million in Q2 2026, and selling, general and administrative expense rose to $17.1 million from $15.8 million over the same two quarters.
  • Interest income of $2,263 thousand and a $6,507 thousand change in fair value of warrant liabilities are reported below operating loss in Q3 2026; the filing does not attribute these to specific causes.

Concerns

  • Cost of sales rose to $5.7 million in Q3 2026 from $4.2 million in Q2 2026, and the filing does not print a gross margin figure.
  • Cash, cash equivalents and short-term investments declined to $134.9 million from $146.8 million in Q2 2026 and from $191,404 thousand at December 31, 2025.
  • Revenue was not recognized for one treatment in Q3 2026 because the associated batch did not meet the identity assay release criterion. The forward-looking statements list manufacturing batch release, biopsy quality and the 84-hour shelf-life as risks to ZEVASKYN revenue.
  • The acquisition of ABO-801 includes $20 million of common stock issued at closing, $30 million payable upon FDA approval and up to an additional $30 million on sales milestones, plus tiered royalties on net sales ranging from low to mid teen percentages.
  • The $30 million private placement was completed after quarter end and is not reflected in the September 30, 2026 cash balance.
  • Interest expense and warrant fair value changes are reported together with operating results, and the filing gives no full-year outlook.

What to watch

  • Quarterly ZEVASKYN treatment count and the number of QTCs that complete treatments, against the cumulative total of 15 treatments and eight QTC sites reported.
  • Effect of NTAP status effective October 1, 2026 on hospital adoption and treatment activity, as the company describes it.
  • Cost of sales relative to product revenue in coming quarters, since no gross margin is printed.
  • Completion and final net proceeds of the $30 million private placement and the use of proceeds described by the company.
  • Cash position against the $134.9 million reported at September 30, 2026, before and after the private placement.
  • Progress of ABO-801 toward regulatory approval, which triggers the $30 million payment to Ellodi.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $134,941 thousand at September 30, 2026, compared with $191,404 thousand at December 31, 2025 and $146.8 million at June 30, 2026.
  • Total assets were $171,924 thousand at September 30, 2026, compared with $219,570 thousand at December 31, 2025.
  • Total liabilities were $46,048 thousand at September 30, 2026, compared with $60,354 thousand at December 31, 2025.
  • Total stockholders' equity was $125,876 thousand at September 30, 2026, compared with $159,216 thousand at December 31, 2025.
  • Common stock outstanding was 57,168,018 at September 30, 2026, compared with 55,043,413 at December 31, 2025.
  • Operating cash flow and free cash flow are not reported in the filing.

Analysis

Abeona reported Q3 2026 product revenue, net, of $13.5 million ($13,491 thousand in the statements), up 18% from $11.4 million in Q2 2026. The filing prints no prior-year Q3 product revenue, as the 2025 column shows a dash. Nine-month 2026 product revenue was $33,591 thousand. The company reports six ZEVASKYN treatments in Q3 2026 and 15 since launch, and states that broader QTC participation supported higher treatment activity. One treatment was not recognized as revenue because its batch did not meet the identity assay release criterion.

Costs moved in different directions. Cost of sales increased to $5,713 thousand from $4.2 million in Q2 2026, and the filing prints no gross margin figure, so margin cannot be read from the document. R&D fell to $3.7 million from $5.0 million in Q2 2026. SG&A rose to $17.1 million from $15.8 million. Total costs and expenses were $26,492 thousand in Q3 2026 against $24,018 thousand in Q3 2025, and loss from operations narrowed to $(13,001) thousand from $(24,018) thousand a year earlier. Net loss was $(4.8) million, or $(0.08) per share, compared with $(20.2) million, or $(0.35) per share, in Q2 2026 and $(5,161) thousand in Q3 2025. The filing does not attribute the sequential narrowing to a single cause, and the below-the-line items (interest income, interest expense and warrant fair value changes) were not explained by the company.

On the balance sheet, cash, cash equivalents and short-term investments were $134.9 million at September 30, 2026, down from $146.8 million at June 30, 2026 and $191,404 thousand at December 31, 2025. The $30 million private placement closed after quarter end and is excluded from that balance. Total assets were $171,924 thousand and stockholders' equity was $125,876 thousand. Operating and free cash flow are not reported.

Capital allocation in the period was dominated by the ABO-801 acquisition from Ellodi Pharmaceuticals. The company issued $20 million of common stock at closing with no upfront cash, and agreed to pay $30 million on FDA approval and up to $30 million on sales milestones, plus royalties. Share count rose: common stock outstanding was 57,168,018 at September 30, 2026, against 55,043,413 at December 31, 2025. The company gives no revenue, margin or expense guidance in this filing, so no forward comparison is possible.

The key items for a reader are the sequential revenue increase, the narrower quarterly loss, the cash decline, and the absence of gross margin and cash flow disclosure. The NTAP designation effective October 1, 2026 is described by the company as expected to support access among eligible Medicare beneficiaries, who the filing says represent approximately 10 percent of RDEB patients.

Management, verbatim

Maximizing the opportunity for ZEVASKYN remains our number one priority. During the third quarter, we continued to build the commercial foundation for ZEVASKYN, with expansion of our QTC network and more centers gaining firsthand treatment experience

Vish Seshadri, Ph.D., Chief Executive Officer, Abeona Therapeutics

Not in the filing

stated, not guessed
  • Gross margin for Q3 2026 and prior periods is not printed.
  • Prior-year (Q3 2025) product revenue value is shown as a dash in the statements, so the comparison is nil and no percentage change is printed.
  • Total revenues for Q2 2026 are not printed; only ZEVASKYN product revenue for Q2 2026 is given in the text.
  • Prior-quarter (Q2 2026) figures for interest income, interest expense, change in fair value of warrant liabilities, other income, income tax, total costs and expenses, and loss from operations are not printed.
  • Year-over-year and quarter-over-quarter percentage changes are not printed for any metric except the 18% sequential revenue increase, which is printed as a percentage without a dollar prior figure beyond the $11.4 million Q2 2026 value.
  • Operating cash flow, investing cash flow and free cash flow are not reported.
  • Company guidance or outlook for 2026 or later periods is not provided; no prior outlook was supplied for comparison.
  • Consensus estimates, analyst expectations and share-price reaction are not in the documents.
  • Net proceeds of the private placement and the number of shares issued in it are not printed.
  • Dec 31, 2025 comparatives for cash, total assets and equity are balance sheet items and are not presented as prior-year or prior-quarter figures in the key metrics.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Abeona Therapeutics filed a Form 8‑K reporting Q3 2026 financials, ZEVASKYN commercial progress, acquisition of ABO‑801, and a $30M PIPE.

Company-level read

Ticker impact

$ABEOBullishHigh confidence
Context

Q3 2026 earnings release with net loss narrowing to $4.8M, revenue $13.5M and $30M PIPE financing disclosed.

Expected impact

potential modest upside as market prices in improved loss profile and new financing.

Evidence & confidence

First‑time disclosure of quarterly results and financing; loss narrowed sharply and cash remains strong.

Market effects

Biotech small‑cap earnings may influence peer valuations in rare‑disease space.

US biotech sector could see slight lift.

Limited to niche biotech investors.

Counterpoint

Losses remain sizable; investors may remain cautious despite cash raise.

Key entities

  • Abeona Therapeutics Inc.

    Biopharma developing ZEVASKYN and ABO‑801.

  • Ellodi Pharmaceuticals

    Seller of ABO‑801 asset.

Every ABEO earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

Med

Abeona Therapeutics Inc. Q3 2026 Earnings Call Summary

Abeona Therapeutics reported 18% Q3 revenue growth for ZEVASKYN, driven by QTC network expansion. The company acquired ABO-801, a Phase III-ready orphan drug with $750M revenue potential. Manufacturing challenges and FDA timelines were discussed. Abeona expects 85-90% long-term gross margins and strengthened commercial foundation by 2027.

$ABEOMed

What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Call

Abeona Therapeutics (ABEO) reported Q3 net loss of $4.8M, down from $20.2M in Q2. The company discussed plans for ABO-801, a drug candidate with potential peak revenue of $750M, targeting a Phase III trial with results expected by late 2028. Abeona also announced a $30M private placement and expects sufficient capital for ABO-801's development. The company's cash position was $134.9M as of September.